Glycopyrronium Doc (Glycopyrronium Bromide)

Glycopyrronium Doc is indicated for the long‑term, once‑daily maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). It helps reduce bronchoconstriction and improve lung function.

• Maintenance therapy for moderate to severe COPD.
• Reduces frequency of COPD exacerbations.
• Improves airflow and reduces dyspnea during daily activities.
• Can be used as part of a combination regimen with other bronchodilators when clinically appropriate.
• May be prescribed for patients who require an anticholinergic inhaled agent.

Potential adverse effects of Glycopyrronium Doc vary in frequency and severity, and most are mild and reversible.

Common

• Dry mouth.
• Cough.
• Throat irritation.
• Upper respiratory tract infection.
• Headache.
• Nausea.

Serious

• Paradoxical bronchospasm.
• Severe allergic reaction (anaphylaxis).
• Urinary retention.
• Cardiac arrhythmia.

Before prescribing Glycopyrronium Doc, clinicians should consider several precautionary factors to ensure safe use.

• Assess for known hypersensitivity to glycopyrronium bromide or other anticholinergics.
• Use cautiously in patients with narrow-angle glaucoma or urinary retention.
• Monitor renal function, as the drug is primarily excreted unchanged in urine.
• Evaluate cardiovascular status, especially in patients with arrhythmias or recent myocardial infarction.
• Advise patients to report persistent dry mouth, throat irritation, or worsening respiratory symptoms.
• Avoid abrupt discontinuation in patients with severe COPD without medical supervision.

Glycopyrronium Doc may interact with other medications; awareness of these interactions helps minimize risk.

Avoid

• Concurrent use with other anticholinergic agents (e.g., ipratropium) that may increase anticholinergic burden.
• Strong anticholinergic drugs that could exacerbate urinary retention or glaucoma.

Use with caution

• Beta‑agonists (short‑acting or long‑acting) when combined, monitor for additive bronchodilator effects.
• Certain antihistamines or tricyclic antidepressants that possess anticholinergic properties.
• Medications affecting renal excretion, such as diuretics, may alter drug clearance.